Reviewing the current picture of uremic toxicity reveals its complexity. Focusing on cardiovascular damage as a model of uremic effects resulting in substantial morbidity and mortality, most molecules with potential to affect the function of a variety of cell types within the vascular system are difficult to remove by dialysis. Examples are the larger middle molecular weight molecules and protein-bound molecules. Recent clinical studies suggest that enhancing the removal of these compounds is beneficial for survival. Future therapeutic options are discussed, including improved removal of toxins and the search for pharmacologic strategies blocking responsible pathophysiologic pathways
renal failure develops, uraemic retention solutes are retained which are normally excreted by the he...
International audienceAdvances in our understanding of uremic retention solutes, and improvements in...
Toxin retention is felt to be a major contributor to the development of uremia in patients with adva...
Reviewing the current picture of uremic toxicity reveals its complexity. Focusing on cardiovascular ...
In the last decade, uremic toxicity as a potential cause for the excess of cardiovascular disease an...
The present review gives an overview of the known and newly detected middle molecules and their biol...
The removal of uremic toxins. Three major groups of uremic solutes can be characterized: the small w...
The uremic syndrome is characterized by an accumulation of uremic toxins due to inadequate kidney fu...
Patients with end-stage kidney disease (ESKD) on maintenance hemodialysis are subject to a high burd...
In patients with severe kidney disease, renal clearance is compromised, resulting in the accumulatio...
Treatment of uremia by hemodialysis has becomewidespread over the last 40 years and has improved sub...
New insights in uremic toxins. The retention in the body of compounds, which normally are secreted i...
Progress in the identification and characterization of uremic retention solutes has refined our unde...
Dialysis technologies have continued to advance over recent decades; however, these advancements hav...
Advances in our understanding of uremic retention solutes, and improvements in hemodialysis membrane...
renal failure develops, uraemic retention solutes are retained which are normally excreted by the he...
International audienceAdvances in our understanding of uremic retention solutes, and improvements in...
Toxin retention is felt to be a major contributor to the development of uremia in patients with adva...
Reviewing the current picture of uremic toxicity reveals its complexity. Focusing on cardiovascular ...
In the last decade, uremic toxicity as a potential cause for the excess of cardiovascular disease an...
The present review gives an overview of the known and newly detected middle molecules and their biol...
The removal of uremic toxins. Three major groups of uremic solutes can be characterized: the small w...
The uremic syndrome is characterized by an accumulation of uremic toxins due to inadequate kidney fu...
Patients with end-stage kidney disease (ESKD) on maintenance hemodialysis are subject to a high burd...
In patients with severe kidney disease, renal clearance is compromised, resulting in the accumulatio...
Treatment of uremia by hemodialysis has becomewidespread over the last 40 years and has improved sub...
New insights in uremic toxins. The retention in the body of compounds, which normally are secreted i...
Progress in the identification and characterization of uremic retention solutes has refined our unde...
Dialysis technologies have continued to advance over recent decades; however, these advancements hav...
Advances in our understanding of uremic retention solutes, and improvements in hemodialysis membrane...
renal failure develops, uraemic retention solutes are retained which are normally excreted by the he...
International audienceAdvances in our understanding of uremic retention solutes, and improvements in...
Toxin retention is felt to be a major contributor to the development of uremia in patients with adva...